Business Description
Starling Oncology Inc
NAICS : 621498
SIC : 8093
ISIN : US68236X1000
Total Employee Number:
641Compare
Compare
Traded in other countries / regions
TOI.USA Index Membership
Russell 2000Russell 3000Russell 3000Russell 2000 IPO Date
2021-11-15Description
Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.29 | |||||
Equity-to-Asset | -0.1 | |||||
Debt-to-Equity | -6.44 | |||||
Debt-to-EBITDA | -3.59 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.19 | |||||
Beneish M-Score | -2.88 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.2 | |||||
3-Year EPS without NRI Growth Rate | 24.7 | |||||
3-Year FCF Growth Rate | 28.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.53 | |||||
9-Day RSI | 49.25 | |||||
14-Day RSI | 49.24 | |||||
3-1 Month Momentum % | 29.41 | |||||
6-1 Month Momentum % | 103.86 | |||||
12-1 Month Momentum % | 31.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.47 | |||||
Quick Ratio | 1.17 | |||||
Cash Ratio | 0.38 | |||||
Days Inventory | 13.89 | |||||
Days Sales Outstanding | 37.69 | |||||
Days Payable | 30.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | -0.06 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 15.12 | |||||
Operating Margin % | -5.99 | |||||
Net Margin % | -7.97 | |||||
EBITDA Margin % | -5.36 | |||||
FCF Margin % | -4.71 | |||||
OCF Margin % | -4 | |||||
ROA % | -26.52 | |||||
ROIC % | -36.58 | |||||
ROC (Joel Greenblatt) % | -71.22 | |||||
ROCE % | -37.5 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.93 | |||||
EV-to-EBIT | -16.32 | |||||
EV-to-EBITDA | -20.1 | |||||
EV-to-Revenue | 1.08 | |||||
EV-to-Forward-Revenue | 0.87 | |||||
EV-to-FCF | -22.83 | |||||
Price-to-GF-Value | 2.26 | |||||
Earnings Yield (Greenblatt) % | -6.13 | |||||
FCF Yield % | -5.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:STLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Starling Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 545.764 | ||
| EPS (TTM) ($) | -0.37 | ||
| Beta | -1.9235 | ||
| 3-Year Sharpe Ratio | 1 | ||
| 3-Year Sortino Ratio | 2.93 | ||
| Volatility % | 64.65 | ||
| 14-Day RSI | 49.24 | ||
| 14-Day ATR ($) | 0.370597 | ||
| 20-Day SMA ($) | 5.379995 | ||
| 12-1 Month Momentum % | 31.02 | ||
| 52-Week Range ($) | 2.32 - 6.67 | ||
| Shares Outstanding (Mil) | 99.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Starling Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Starling Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 17:00 | In 101 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 100 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 17:00 | In 2 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 1 day | ||
| General meeting for 2026 | 2026-06-10 09:00 | 4.96 (-1.98%) | ||
| B. Riley Securities Institutional Investor Conference | 2026-05-21 21:00 | 4.20 (+2.19%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 17:30 | 3.80 (-4.52%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 3.80 (-4.52%) | ||
| 25th Annual Needham Healthcare Conference | 2026-04-15 15:45 | 3.38 (+1.81%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 17:00 | 2.76 (+5.34%) |
Show
Entries
Starling Oncology Inc Frequently Asked Questions
What is Starling Oncology Inc(STLN)'s stock price today?
The current price of STLN is $5.17. The 52 week high of STLN is $6.67 and 52 week low is $2.32.
When is next earnings date of Starling Oncology Inc(STLN)?
The next earnings date of Starling Oncology Inc(STLN) is 2026-08-06.
Does Starling Oncology Inc(STLN) pay dividends? If so, how much?
Starling Oncology Inc(STLN) does not pay dividend.
Guru Commentaries on NAS:STLN
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| The Oncology Institute Announces a Strategic Partnership with IDEOlogy Health to Provide Customized Medical Education | 2023-05-04 |
Articles on Starling Oncology Inc
Insider Buying: Jorey Chernett Acquires Additional Shares of The Oncology Institute Inc (TOI)
Jul 22, 2026
Insider Buying: Jorey Chernett Acquires Additional Shares of The Oncology Institute Inc (TOI)
Jul 13, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers